The CELx HSF test was used to determine the amount of HER2 participation in NRG1b- and EGF-driven activity in the HER2+ (n = 9) and HER2- (n = 10) breast cancer cell lines in the presence and absence of pertuzumab. This evidence concerns the gene ERBB2 and breast carcinoma.